Today: 30 June 2026
KLA stock price tumbles 15% after earnings — what traders watch next for KLAC
2 February 2026
1 min read

KLA stock price tumbles 15% after earnings — what traders watch next for KLAC

New York, Feb 1, 2026, 18:17 ET — The market has closed.

  • KLA shares ended Friday at $1,427.94, slipping roughly 15%.
  • The decline came after the company’s quarterly update, as investors dug into its outlook on chip-tool demand.
  • Attention turns to Monday’s open and crucial U.S. data scheduled for later this week.

KLA shares dropped 15.2% on Friday, closing at $1,427.94. Investors dumped the chipmaking equipment maker after its recent forecast fell short of expectations following a strong pre-earnings rally.

Markets are closed for the weekend, putting the spotlight on the stock ahead of Monday’s session. Traders will watch closely to see if the selloff was just a one-day dip or the beginning of a deeper slide.

KLA holds a key role as a top supplier of inspection and metrology equipment — the “process control” gear that helps chipmakers detect defects and boost yields. Its forecasts frequently influence projections for wafer fab equipment (WFE) spending, the crucial chip factory tool budget.

KLA exceeded Wall Street expectations for both quarterly revenue and adjusted earnings, and its guidance for the March quarter came in broadly ahead of estimates. Yet, shares dropped roughly 7% in after-hours trading. Michael Ashley Schulman, CIO at Running Point Capital Advisors, noted the stock had “already sprinted into the print” and described the March-quarter outlook as “steady growth rather than renewed acceleration.” Reuters

CEO Rick Wallace called it a “record quarter” in the earnings release, highlighting strong process control demand from top-tier foundry, logic, and memory sectors. He also noted KLA is benefiting from the surge in AI infrastructure investment. KLA Corporation

Analysts wasted no time debating how much upside remains after KLA’s recent surge — and whether the company’s cautious take on WFE spending signals caution or a red flag. Needham’s Charles Shi said it’s “too early to call a race,” while UBS’s Timothy Arcuri trimmed his price target and held a neutral rating. J.P. Morgan’s Harlan Sur, meanwhile, pushed his target higher and stayed bullish. Barron’s

Peers have shifted the benchmark. Lam Research, for instance, recently predicted revenue that beat estimates. CEO Tim Archer commented, “Entering 2026, our expanding product and services portfolio is enabling the market’s transition” toward more complex devices and packages. Reuters

Downside risks are spelled out in KLA’s latest quarterly filing. The company pointed to changing export regulations that could limit sales and service to some Chinese clients, alongside tariffs and fluctuations in customer capital expenditures.

On Monday, investors will watch closely for signals from chip-tool peers and major chip buyers. They’ll also be gauging if bargain hunters step in after the stock tumbled well below last week’s peaks.

Upcoming key events include Monday’s release of the Institute for Supply Management’s U.S. manufacturing PMI at 10:00 a.m. ET. Then on Friday, the U.S. Bureau of Labor Statistics will publish the Employment Situation report at 8:30 a.m. ET.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday
Previous Story

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday

OCBC stock price drops in Singapore as metals rout jolts markets; earnings next
Next Story

OCBC stock price drops in Singapore as metals rout jolts markets; earnings next

Go toTop